Business Description
Everest Medicines Ltd
ISIN : KYG3224E1061
Share Class Description:
STU:6HN: Ordinary SharesTotal Employee Number:
812Compare
Compare
Traded in other countries / regions
01952.Hong Kong6HN.Germany IPO Date
2021-06-02Description
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.95 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -2.22 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.49 | |||||
Beneish M-Score | -1.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 388.7 | |||||
3-Year EBITDA Growth Rate | -22.6 | |||||
3-Year EPS without NRI Growth Rate | 54.9 | |||||
3-Year FCF Growth Rate | 37.6 | |||||
3-Year Book Growth Rate | -6.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 79.17 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 47.01 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.16 | |||||
9-Day RSI | 42.65 | |||||
14-Day RSI | 43.73 | |||||
3-1 Month Momentum % | -32.55 | |||||
6-1 Month Momentum % | -29.21 | |||||
12-1 Month Momentum % | -64.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.89 | |||||
Quick Ratio | 4.85 | |||||
Cash Ratio | 3.96 | |||||
Days Inventory | 12.68 | |||||
Days Sales Outstanding | 82.14 | |||||
Days Payable | 68.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -21.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.26 | |||||
Operating Margin % | -21.59 | |||||
Net Margin % | -17.34 | |||||
EBITDA Margin % | -24.49 | |||||
FCF Margin % | -25.8 | |||||
OCF Margin % | -5.38 | |||||
ROE % | -6.75 | |||||
ROA % | -5.36 | |||||
ROIC % | -5.48 | |||||
3-Year ROIIC % | -119.32 | |||||
ROC (Joel Greenblatt) % | -82.33 | |||||
ROCE % | -11.69 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 24.32 | |||||
PS Ratio | 4.67 | |||||
PB Ratio | 1.54 | |||||
Price-to-Tangible-Book | 2.57 | |||||
EV-to-EBIT | -10.99 | |||||
EV-to-Forward-EBIT | 3.52 | |||||
EV-to-EBITDA | -15.1 | |||||
EV-to-Forward-EBITDA | 3.42 | |||||
EV-to-Revenue | 3.7 | |||||
EV-to-Forward-Revenue | 2.94 | |||||
EV-to-FCF | -14.36 | |||||
Price-to-GF-Value | 0.09 | |||||
| Price-to-Net-Current-Asset-Value | 4.44 | |||||
| Price-to-Net-Cash | 6.83 | |||||
Earnings Yield (Greenblatt) % | -9.1 | |||||
FCF Yield % | -5.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Everest Medicines Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 206.711 | ||
| EPS (TTM) (€) | -0.108 | ||
| Beta | -2.1245 | ||
| 3-Year Sharpe Ratio | 0.25 | ||
| 3-Year Sortino Ratio | 0.48 | ||
| Volatility % | 28.97 | ||
| 14-Day RSI | 43.73 | ||
| 14-Day ATR (€) | 0.125646 | ||
| 20-Day SMA (€) | 2.879 | ||
| 12-1 Month Momentum % | -64.03 | ||
| 52-Week Range (€) | 2.52 - 8.25 | ||
| Shares Outstanding (Mil) | 351.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Everest Medicines Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Everest Medicines Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Everest Medicines Ltd Frequently Asked Questions
What is Everest Medicines Ltd(STU:6HN)'s stock price today?
The current price of STU:6HN is €2.80. The 52 week high of STU:6HN is €8.25 and 52 week low is €2.52.
When is next earnings date of Everest Medicines Ltd(STU:6HN)?
The next earnings date of Everest Medicines Ltd(STU:6HN) is .
Does Everest Medicines Ltd(STU:6HN) pay dividends? If so, how much?
Everest Medicines Ltd(STU:6HN) does not pay dividend.
Press Release
Articles on Everest Medicines Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers